Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared a post on X:
“Laurence Albiges at AACRkidney2026 on implementing pragmatic biomarkers into RCC clinical trials.
PD-L1 as a pragmatic marker: locally read with 92% concordance to central staining. A strong foundation for decentralized biomarker strategy.
CARE1 insights:
- High proportion of aggressive disease and PD-L1 positive patients.
- Patient population notably different from CheckMate 214.
- Tissue availability remains a real challenge.
Massive collaborative effort: EU philanthropic + national funding driving this forward. Site activation timelines improving as the network scales.
And in the adjuvant space: KIM-1 data from IMotion010 is compelling:
- KIM-1 may enhance identification of patients most likely to benefit.
- Combining KIM-1 with T stage could sharpen patient selection for adjuvant therapy.
- Exactly the kind of biomarker-driven precision we need in this space to prevent overtreatment.
Pragmatic does not mean imprecise. It means actionable.”
Other articles featuring Katy Beckermann on OncoDaily.
